Where does Roche Diabetes Care, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Roche Diabetes Care, Inc. ranks #750 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Roche Diabetes Care, Inc. hold?

Roche Diabetes Care, Inc. holds 610 US utility patents granted between 2015 and 2025, spanning 103 technology areas.

What is Roche Diabetes Care, Inc.'s Innovation Score?

Roche Diabetes Care, Inc. has an Innovation Score of 62.0 out of 100 (top 3% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Roche Diabetes Care, Inc. focus on?

Roche Diabetes Care, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 306 patents, ranking #68 of 7,127 assignees active in that subclass. Grants appear in 103 CPC subclasses total.

Is Roche Diabetes Care, Inc.'s patent grant rate increasing or decreasing?

Roche Diabetes Care, Inc.'s recent grant velocity is -22% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Roche Diabetes Care, Inc.'s patents?

Roche Diabetes Care, Inc.'s patents average 17.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Roche Diabetes Care, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Roche Diabetes Care, Inc.

USPTO PatentsView assignee record - 610 granted patents across 103 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Roche ranks #750 of 49,997 tracked US assignees by granted-patent volume, with 610 patents across 103 technology areas.

#750
of 49,997 US assignees by volume: Top 3%
by Innovation Score (62.0/100): 17.2
avg claims per patent: -22%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R750 · US Corporation #750 · 610 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-MID 610 grants
TOP-DECILE #750/49,997
PHOTO-FINISH Renault S
CPC-WIDE A61B · 103 areas
INNOV-STRONG 62.0/100
CLAIMS-RICH 17.2 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -22% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Renault S.A.S. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Roche’s 62.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 22.2 pts (36%) Velocity 4.5 pts (7%) Breadth 25.0 pts (40%) Claim depth 10.3 pts (17%)

Qualcomm Incorporated · highest

85
Precision Planting · near

62
Roche Diabetes Care · this assignee

62
Thermo King · near

62
Arthrex · near

62
G D S P A · near

62
3D Lighting… · lowest

7

What this shows Roche's Innovation Score is 62.0/100 (top 3% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Roche?

Each dot is one of Roche’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Roche’s own 17.2 claims/patent is ABOVE the 11.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Roche vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

How Roche's grant cadence moved

Between 2020–2024, Roche Diabetes Care, Inc. received 256 grants versus 328 in 2015–2019 (-22% equal-window velocity, below median growth). Across complete PatentsView years, output peaked in 2016 at 84 grants and bottomed in 2015 at 33. Lead class A61B accounts for 50.2% of the portfolio across 103 subclasses. Volume neighbours: Ford Motor Company (#746) and GE Aviation Systems Limited (#754).

Roche's three-year grant acceleration

From 2019–2021 to 2022–2024, Roche Diabetes Care, Inc. moved from 202 to 135 grants (0.67x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,249. See the growth leaderboard.

Ford Motor

612
Spectrum Brands

612
Yahoo Holdings

611
Renault S

610
SK Innovation

610
Roche Diabetes Ca… ◀

610
Oki Data

609
University of Uta…

608
GE Aviation Syste…

607

What this shows Roche holds 610 patents at rank #750, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Roche

By rank, the assignees closest to #750 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Roche's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Roche, neither rank-band nor same-CPC leaders (those blocks stay above). In A61B (Diagnosis), Roche ranks #68 of 7,127 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (62 here).

Thermo King LLC 62 Arthrex, Inc. 62 Precision Planting LLC 62 G.D S.P.A. 62

Similar claim depth

Nearest assignees by average claims per patent (17.2 here).

Regal Beloit America, Inc. 17.2 avg Queen's University at Kingston 17.2 avg Promerus, LLC 17.2 avg Kapsch TrafficCom AG 17.2 avg

Roche's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

62 Top 3% higher than 97% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Roche Diabetes Care, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	33	5.4%
2016	84	13.8%
2017	60	9.8%
2018	70	11.5%
2019	81	13.3%
2020	61	10.0%
2021	60	9.8%
2022	54	8.9%
2023	37	6.1%
2024	44	7.2%
2025partial year	26	4.3%

Which technologies does Roche Diabetes Care, Inc. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 306

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 202

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 173

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 147

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 63

G06F - Electric Digital Data Processing 47

Y10T - Technical Subjects Covered BY Former US Classification 44

H04L - Transmission OF Digital Information, e.g. Telegraphic Communication 26

H04W - Wireless Communication Networks 23

B01L - Chemical OR Physical Laboratory Apparatus FOR General USE 23

G06T - Image Data Processing OR Generation, IN General 16

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 14

G08B - Signalling OR Calling SYSTEMS; Order TELEGRAPHS; Alarm Systems 13

C12Y - Enzymes 11

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 11

Top 15 of 103 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Roche Diabetes Care, Inc.'s patent record in context - here's where to go next.

Roche Diabetes Care, Inc.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 50.2% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #750 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Roche Diabetes Care, Inc. against Ford Motor Company, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 62.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.